Oncology-focused medical technology company TriSalus Life Sciences Inc. (TLSI) is gaining momentum as it expands its Pressure-Enabled Drug Delivery (PEDD) platform and TriNav product suite across solid tumor indications. With Phase I PERIO studies now complete and final data readouts expected in Q4 2025, the company is positioned at the intersection of commercial adoption and clinical innovation, making TLSI a compelling stock to watch in oncology-focused medical technology.
Launch of TriNav XP
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com